Everest Medicines gets NMPA approval for CARDAMYST in adult PSVT
Everest Medicines said China’s NMPA approved CARDAMYST (etripamil) to convert acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
HONG KONG, Sept 3, 2026 - (ACN Newswire) - Everest Medicines said China’s National Medical Products Administration (NMPA) has approved CARDAMYST(R) (etripamil) for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.